Michael Kozub - Elixxer Corporate Secretary
| ELXR Stock | CAD 1.15 0.00 0.00% |
Insider
Michael Kozub is Corporate Secretary of Elixxer since 2018.
| Tenure | 6 years |
| Address | 1100 Boulevard Rene- Levesque Ouest, Montreal, QC, Canada, H5B 4N4 |
| Phone | 514 788 1499 |
| Web | https://www.elixxer.com |
Elixxer Management Efficiency
The company has return on total asset (ROA) of (0.3042) % which means that it has lost $0.3042 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (10.1376) %, meaning that it generated substantial loss on money invested by shareholders. Elixxer's management efficiency ratios could be used to measure how well Elixxer manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Elixxer's Total Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to climb to about 8.8 M in 2024, whereas Total Assets are likely to drop slightly above 5.9 M in 2024.Management Performance
| Return On Equity | -10.14 | ||||
| Return On Asset | -0.3 |
Elixxer Leadership Team
Elected by the shareholders, the Elixxer's board of directors comprises two types of representatives: Elixxer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elixxer. The board's role is to monitor Elixxer's management team and ensure that shareholders' interests are well served. Elixxer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elixxer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Lenigas, Co-Chairman of the Board | ||
| CPA CMA, Corporate CFO | ||
| Anthony Samaha, Director | ||
| Jeanne Wyk, Vice Communications | ||
| Michael Kozub, Corporate Secretary | ||
| Jeff Cheah, Director | ||
| John McMullen, President | ||
| Mazen Haddad, Co-Chairman of the Board, Chief Executive Officer | ||
| Daniel Lubienietzky, VP Development | ||
| Richard Widmann, EVP Commercial | ||
| Kym No, Interim Chief Financial Officer | ||
| Mohammed Ghafari, Independent Director | ||
| Tarik Alhaidary, Director | ||
| Ferras Zalt, Executive Chairman of the Board | ||
| Rafi Hazan, Director | ||
| Remy Meglio, Chief Operating Officer | ||
| LLB LLB, Legal Council |
Elixxer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elixxer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elixxer Stock Analysis
When running Elixxer's price analysis, check to measure Elixxer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elixxer is operating at the current time. Most of Elixxer's value examination focuses on studying past and present price action to predict the probability of Elixxer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elixxer's price. Additionally, you may evaluate how the addition of Elixxer to your portfolios can decrease your overall portfolio volatility.